Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Solventum Corporation
SOLV
NYSE·Healthcare·Medical - Care Facilities·Mkt cap $13.6B
$78.64
▲ +0.37%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$62.38 - $88.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 0.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive healthcare technology portfolio
- Advanced medical device innovation
- Integrated software and hardware solutions
- Diversified revenue streams
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Healthcare technology digital transformation
Value
Undervalued - trading well below Healthcare Facilities peers
Momentum
Hot
+23.3% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying SOLV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 5, 2026
Reported EPS of $1.48 vs $1.35 consensus (+9.6% surprise). Revenue of $2.0B vs $2.0B expected (+2.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.6%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
+2%
+3%
+4%
+1%
-4%
-3%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.1B
$2.1B
$2.1B
$2.1B
$2.2B
$2.1B
$2.0B
$2.0B
Margins · last 8Q
Gross
—
Operating
—
Profit
0.7%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
29%
Sell
0%
Median Price Target
$92.00
▲ +17.0% vs $78.64
Latest: Jefferies · $43.00 · Jun 1, 2026
6 analysts covering